Skip to main content Accessibility help
×
Home

Antiretroviral Drug Resistance in Human Immunodeficiency Virus–Infected Source Patients for Occupational Exposures to Healthcare Workers

  • Elise M. Beltrami (a1), Rachanee Cheingsong (a2), Walid M. Heneine (a2), Richard A. Respess (a2), Jean G. Orelien (a3), Meryl H. Mendelson (a4), Mari A. Stewart (a5), Brian S. Koll (a6), Carol A. Sulis (a7), Denise M. Cardo (a1) and Occupational HIV Exposure Study Group...

Abstract

Objective:

To assess the prevalence of HIV antiretroviral resistance among source patients for occupational HIV exposures.

Design:

Blood and data (eg, stage of HIV, previous antiretroviral drug therapy, and HIV RNA viral load) were collected from HIV-infected patients who were source patients for occupational exposures.

Setting:

Seven tertiary-care medical centers in five U.S. cities (San Diego, California; Miami, Florida; Boston, Massachusetts; Albany, New York; and New York, New York [three sites]) during 1998 to 1999.

Participants:

Sixty-four HIV-infected patients who were source patients for occupational exposures.

Results:

Virus from 50 patients was sequenced; virus from 14 patients with an undetectable (ie, < 400 RNA copies/mL) viral load could not be sequenced. Overall, 19 (38%) of the 50 patients had primary eenotypic mutations associated with resistance to reverse transcriptase or protease inhibitors. Eighteen of the 19 viruses with primary mutations and 13 wild type viruses were phenotyped by recombinant assays; 19 had phenotypic resistance to at least one antiretroviral agent. Of the 50 source patients studied, 26 had taken antiretroviral agents in the 3 months before the occupational exposure incident. Sixteen (62%) of the 26 drug-treated patients had virus that was phenotypically resistant to at least one drug. Four (17%) of 23 untreated patients had phenotypically resistant virus. No episodes of HIV transmission were observed among the exposed HCWs.

Conclusions:

There was a high prevalence of drug-resistant HIV among source patients for occupational HIV exposures. Healthcare providers should use the drug treatment information of source patients when making decisions about postexposure prophylaxis.

Copyright

Corresponding author

Division of Healthcare Quality Promotion, Mailstop E-68, Centers for Disease Control and Prevention, 1600 Clifton Road, Atlanta, GA 30333

References

Hide All
1.Centers for Disease Control and Prevention. Updated U.S. Public Health Service guidelines for the management of occupational exposures to HBV, HCV, and HIV and recommendations for postexposure prophylaxis. MMWR 2001;50(RR11):152.
2.Hirsch, MS, Brun-Vézinet, F, D'Aquila, RT, et al.Antiretroviral drug resistance testing in adult HIV-1 infection: recommendations of an International AIDS Society-USA panel. JAMA 2000;283:24172426.
3.Lot, F, Abiteboul, D. Occupational HIV infection in France. Presented at the 4th Annual International Conference on Occupational Health for Health Care Workers; September 28-October 1, 1999; Montreal, Quebec, Canada. Abstract WP-25.
4.Perdue, B, Wolde Rufael, D, Mellors, J, Quinn, T, Margolick, J. HIV-1 transmission by a needlestick injury despite rapid initiation of fourdrug postexposure prophylaxis. Presented at the 6th Annual Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, IL. Abstract 210.
5.Beltrami, EM, Luo, C-C, de la Torre, N, Cardo, DM. Transmission of drug-resistant HIV after an occupational exposure despite postexposure prophylaxis with a combination drug regimen. Infect Control Hosp Epidemiol 2002;23:345348.
6.Tack, PC, Bremer, JW, Harris, AA, Landay, AL, Kessler, HA, Kuritzkes, DR. Genotypic analysis of HIV-1 isolates to identify antiretroviral resistance mutations from source patients involved in health care worker occupational exposures. JAMA 1999;281:10851086. Letter.
7.Mehta, CR, Patel, N. Exact logistic regression: theory and examples. Stat Med 1995;14:21432160.
8.Roland, ME, Martin, JN, Grant, RM, et al. Who is the source of HIV exposure in the San Francisco Post-Exposure Prevention (PEP) Project? Presented at the 7th Annual Conference on Retroviruses and Opportunistic Infections; January 30-February 2, 2000; San Francisco, CA. Abstract 197.
9.Weinstock, H, Respess, R, Heneine, W, et al.Prevalence of mutations associated with human immunodeficiency virus type 1 seroconverters in the United States, 1992-1998. J Infect Dis 2000;182:330333.
10.Boden, D, Hurley, A, Zhang, L, et al.HIV-1 drug resistance in newly infected individuals. JAMA 1999;282:11351141.
11.Brodine, SK, Shaffer, RA, Starkey, MJ, et al.Drug resistance patterns, genetic subtypes, clinical features, and risk factors in military personnel with HIV-1 seroconversion. Ann Intern Med 1999;131:502506.
12.Leigh-Brown, AJ, Precious, HM, Whitcomb, JM, et al.Reduced susceptibility of human immunodeficiency virus type 1 (HIV 1) from patients with primary HIV infection to nonnucleoside reverse transcriptase inhibitors is associated with variation at novel amino acid sites. J Virol 2000;74:1026910273.
13.Quinn, TC, Wawer, MJ, Sewankambo, N, et al.Viral load and heterosexual transmission of human immunodeficiency virus type 1. N Engl J Med 2000;342:921929.
14.Ragni, MV, Faruki, H, Kingsley, LA. Heterosexual HIV-1 transmission and viral load in hemophilic patients. J Acquir Immune Defic Syndr 1998;7:4245.
15.Hisada, M, O'Brien, TR, Rosenberg, PS, Goedert, JJ. Virus load and risk of heterosexual transmission of human immunodeficiency virus and hepatitis C virus by men with hemophilia. J Infect Dis 2000;181:14751478.
16.Pedraza, MA, del Romero, J, Roldan, F, et al.Heterosexual transmission of HIV-1 is associated with high plasma viral load levels and a positive viral isolation in the infected partner. J Acquir Immune Defic Syndr 1999;21:120125.
17.Mofenson, LM, Lambert, JS, Stiehm, ER, et al.Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine. N Engl J Med 1999;341:385393.
18.Garcia, PM, Kalish, LA, Pitt, J, et al.Maternal levels of plasma human immunodeficiency virus type 1 RNA and the risk of perinatal transmission. N Engl J Med 1999;341:394402.
19.Dickover, RE, Garratty, EM, Herman, SA, et al.Identification of levels of maternal HIV-1 RNA associated with risk of perinatal transmission: effect of maternal zidovudine treatment on viral load. JAMA 1996;275:599605.
20.Eastman, PS, Shapiro, DE, Coombs, RW, et al.Maternal viral genotypic zidovudine resistance and infrequent failure of zidovudine therapy to prevent perinatal transmission of human immunodeficiency virus type 1 in Pediatric AIDS Clinical Trials Group Protocol 076. J Infect Dis 1998;177:557564.
21.Blanche, S, Rouzioux, C, Mandelbrot, L, Delfraissy, JF, Mayaux, MJ. Zidovudine-lamivudine for prevention of mother to child HIV-1 transmission. Presented at the 6th Annual Conference on Retroviruses and Opportunistic Infections; January 31-February 4, 1999; Chicago, IL. Abstract 267.
22.Devereux, HL, Youle, M, Johnson, MA, Loveday, C. Rapid decline in detectability of HIV-1 drug resistance mutations after stopping therapy. AIDS 1999;13:F123F127.
23.Verhofsted, C, Van Wanzeele, F, Van Der Gucht, B, De Cabooter, N, Plum, J. Interruption of reverse transcriptase inhibitors or a switch from reverse transcriptase to protease inhibitors resulted in a fast reappearance of virus strains with a reverse transcriptase inhibitor-sensitive genotype. AIDS 1999;13:25412546.

Antiretroviral Drug Resistance in Human Immunodeficiency Virus–Infected Source Patients for Occupational Exposures to Healthcare Workers

  • Elise M. Beltrami (a1), Rachanee Cheingsong (a2), Walid M. Heneine (a2), Richard A. Respess (a2), Jean G. Orelien (a3), Meryl H. Mendelson (a4), Mari A. Stewart (a5), Brian S. Koll (a6), Carol A. Sulis (a7), Denise M. Cardo (a1) and Occupational HIV Exposure Study Group...

Metrics

Altmetric attention score

Full text views

Total number of HTML views: 0
Total number of PDF views: 0 *
Loading metrics...

Abstract views

Total abstract views: 0 *
Loading metrics...

* Views captured on Cambridge Core between <date>. This data will be updated every 24 hours.

Usage data cannot currently be displayed